TY - JOUR
T1 - Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT)
T2 - Rationale and design of a meta-analysis project
AU - Lorenz, Matthias W.
AU - Bickel, Horst
AU - Bots, Michiel L.
AU - Breteler, Monique M.B.
AU - Catapano, Alberico L.
AU - Desvarieux, Moise
AU - Hedblad, Bo
AU - Iglseder, Bernhard
AU - Johnsen, Stein Harald
AU - Juraska, Michal
AU - Kiechl, Stefan
AU - Mathiesen, Ellisiv B.
AU - Norata, Giuseppe D.
AU - Grigore, Liliana
AU - Polak, Joseph
AU - Poppert, Holger
AU - Rosvall, Maria
AU - Rundek, Tatjana
AU - Sacco, Ralph L.
AU - Sander, Dirk
AU - Sitzer, Matthias
AU - Steinmetz, Helmuth
AU - Stensland, Eva
AU - Willeit, Johann
AU - Witteman, Jacqueline
AU - Yanez, David
AU - Thompson, Simon G.
PY - 2010/5
Y1 - 2010/5
N2 - Carotid intima media thickness (IMT) progression is increasingly used as a surrogate for vascular risk. This use is supported by data from a few clinical trials investigating statins, but established criteria of surrogacy are only partially fulfilled. To provide a valid basis for the use of IMT progression as a study end point, we are performing a 3-step meta-analysis project based on individual participant data. Objectives of the 3 successive stages are to investigate (1) whether IMT progression prospectively predicts myocardial infarction, stroke, or death in population-based samples; (2) whether it does so in prevalent disease cohorts; and (3) whether interventions affecting IMT progression predict a therapeutic effect on clinical end points. Recruitment strategies, inclusion criteria, and estimates of the expected numbers of eligible studies are presented along with a detailed analysis plan.
AB - Carotid intima media thickness (IMT) progression is increasingly used as a surrogate for vascular risk. This use is supported by data from a few clinical trials investigating statins, but established criteria of surrogacy are only partially fulfilled. To provide a valid basis for the use of IMT progression as a study end point, we are performing a 3-step meta-analysis project based on individual participant data. Objectives of the 3 successive stages are to investigate (1) whether IMT progression prospectively predicts myocardial infarction, stroke, or death in population-based samples; (2) whether it does so in prevalent disease cohorts; and (3) whether interventions affecting IMT progression predict a therapeutic effect on clinical end points. Recruitment strategies, inclusion criteria, and estimates of the expected numbers of eligible studies are presented along with a detailed analysis plan.
UR - http://www.scopus.com/inward/record.url?scp=77951674231&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2010.02.008
DO - 10.1016/j.ahj.2010.02.008
M3 - Article
C2 - 20435179
AN - SCOPUS:77951674231
SN - 0002-8703
VL - 159
SP - 730-736.e2
JO - American Heart Journal
JF - American Heart Journal
IS - 5
ER -